Literature DB >> 24379135

Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.

Luca Quagliata1, Sandra Klusmeier, Natascha Cremers, Bronislaw Pytowski, Alfred Harvey, Ronald J Pettis, Wilko Thiele, Jonathan P Sleeman.   

Abstract

For many types of human cancer, the expression of vascular endothelial growth factor-C (VEGF-C) correlates with enhanced tumor-associated lymphatic vessel density, metastasis formation and poor prognosis. In experimental animals, VEGF-C produced by primary tumors can induce lymphangiogenesis within and/or at the periphery of the tumor, and promotes metastasis formation. Tumor-induced lymphangiogenesis is therefore thought to expedite entry of tumor cells into the lymphatic vasculature and their trafficking to regional lymph nodes, thereby fostering metastatic dissemination. Tumour-produced VEGF-C can also drain to the regional lymph nodes and induce lymphangiogenesis there. Whether this activity promotes metastasis formation remains unclear. To address this issue we manipulated VEGF-C activity and VEGFR-3 activation in the lymph nodes draining syngeneic rat breast cancers using intra-dermal delivery of either recombinant VEGF-C or VEGFR-3 blocking antibodies to induce or suppress lymph node lymphangiogenesis, respectively. Recombinant VEGF-C induced lymph node lymphangiogenesis, but was not sufficient to promote metastasis formation by poorly metastatic NM-081 breast tumours. Conversely, inhibition of lymph node lymphangiogeneis induced by highly metastatic MT-450 breast tumours suppressed the outgrowth of lymph node metastases, but not the initial colonization of the lymph nodes. Lung metastasis was also not affected. We conclude that tumor-derived VEGF-C draining to regional lymph nodes promotes the outgrowth of lymph node metastases. VEGF-C may induce lung metastasis independently of its effects on lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24379135     DOI: 10.1007/s10585-013-9633-2

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  47 in total

1.  Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis.

Authors:  Maria I Harrell; Brian M Iritani; Alanna Ruddell
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 2.  Tumor metastasis and the lymphatic vasculature.

Authors:  Jonathan P Sleeman; Wilko Thiele
Journal:  Int J Cancer       Date:  2009-12-15       Impact factor: 7.396

3.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium.

Authors:  Tara Karnezis; Ramin Shayan; Carol Caesar; Sally Roufail; Nicole C Harris; Kathryn Ardipradja; You Fang Zhang; Steven P Williams; Rae H Farnsworth; Ming G Chai; Thusitha W T Rupasinghe; Dedreia L Tull; Megan E Baldwin; Erica K Sloan; Stephen B Fox; Marc G Achen; Steven A Stacker
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

4.  A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities.

Authors:  V Joukov; V Kumar; T Sorsa; E Arighi; H Weich; O Saksela; K Alitalo
Journal:  J Biol Chem       Date:  1998-03-20       Impact factor: 5.157

5.  Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis.

Authors:  S J Mandriota; L Jussila; M Jeltsch; A Compagni; D Baetens; R Prevo; S Banerji; J Huarte; R Montesano; D G Jackson; L Orci; K Alitalo; G Christofori; M S Pepper
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

6.  Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

Authors:  Nicole Roberts; Bryan Kloos; Melanie Cassella; Simona Podgrabinska; Kris Persaud; Yan Wu; Bronislaw Pytowski; Mihaela Skobe
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

7.  Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C.

Authors:  Kris Persaud; Jean-Christophe Tille; Meilin Liu; Zhenping Zhu; Xenia Jimenez; Daniel S Pereira; Hua-Quan Miao; Laura A Brennan; Larry Witte; Michael S Pepper; Bronislaw Pytowski
Journal:  J Cell Sci       Date:  2004-05-18       Impact factor: 5.285

8.  Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients.

Authors:  Ying-Chun Zhao; Xiao-Jian Ni; Ming-Hai Wang; Xiao-Ming Zha; Yi Zhao; Shui Wang
Journal:  Med Oncol       Date:  2012-05-06       Impact factor: 3.064

9.  VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis.

Authors:  Wilko Thiele; Jaya Krishnan; Melanie Rothley; Debra Weih; Diana Plaumann; Vanessa Kuch; Luca Quagliata; Herbert A Weich; Jonathan P Sleeman
Journal:  Blood       Date:  2012-07-13       Impact factor: 22.113

10.  p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis.

Authors:  A Ruddell; K S Kelly-Spratt; M Furuya; S S Parghi; C J Kemp
Journal:  Oncogene       Date:  2007-12-03       Impact factor: 9.867

View more
  8 in total

Review 1.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

Review 2.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

3.  Novel application assigned to toluquinol: inhibition of lymphangiogenesis by interfering with VEGF-C/VEGFR-3 signalling pathway.

Authors:  M García-Caballero; S Blacher; J Paupert; A R Quesada; M A Medina; A Noël
Journal:  Br J Pharmacol       Date:  2016-05-04       Impact factor: 8.739

Review 4.  Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis.

Authors:  Simona L Schlereth; Nasrin Refaian; Sandra Iden; Claus Cursiefen; Ludwig M Heindl
Journal:  Biomed Res Int       Date:  2014-09-01       Impact factor: 3.411

Review 5.  Deciphering Pro-Lymphangiogenic Programs during Mammary Involution and Postpartum Breast Cancer.

Authors:  Virginia F Borges; Alan M Elder; Traci R Lyons
Journal:  Front Oncol       Date:  2016-11-02       Impact factor: 6.244

Review 6.  Lymph Nodes and Cancer Metastasis: New Perspectives on the Role of Intranodal Lymphatic Sinuses.

Authors:  Rui-Cheng Ji
Journal:  Int J Mol Sci       Date:  2016-12-28       Impact factor: 5.923

7.  Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis.

Authors:  Meng Sha; Seogsong Jeong; Xiao-Song Chen; Ying Tong; Jie Cao; Han-Yong Sun; Lei Xia; Ning Xu; Xin Wang; Long-Zhi Han; Zhi-Feng Xi; Jian-Jun Zhang; Xiao-Ni Kong; Qiang Xia
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

Review 8.  Lymphatics in Tumor Progression and Immunomodulation.

Authors:  Claire Y Li; Stav Brown; Babak J Mehrara; Raghu P Kataru
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.